Market Challenges And Opportunities
Zambia Cholera Vaccines Market- Drivers
- Increasing government initiatives: Increasing government initiatives is expected to drive the growth of the market over the forecast period. For instance, in June 2021, World Health Organization (WHO) supported the cholera vaccination campaign in Zambia’s hot spot districts as the country accelerates its efforts to eliminate the deadly disease. The World Health Organization has supported the country in conducting the situation analysis, mapping of the hotspots and has worked with the Global Alliance for Vaccines and Immunizations (GAVI) and the Global Task Force on Cholera Control (GTFCC) to ensure that the country receives the life-saving vaccines.
- Increasing adoption of inorganic growth strategies: Increasing adoption of inorganic growth strategies such as agreement by the key market players in the market is expected to drive the growth of the market over the forecast period. For instance, in November 2022, Biovac, a global pharmaceutical company, announced that it has entered into licensing and technology transfer agreement with the International Vaccine Institute (IVI), a non-profit international organization, for the manufacture of an oral cholera vaccine (OCV), for African and global market.
Zambia Cholera Vaccines Market- Opportunities
- Increasing launch of campaigns: Increasing launch of campaigns is expected to drive the growth of the market over the forecast period. For instance, in February 2022, the government of Zambia launched an oral cholera vaccination campaign in Lusaka, the country's capital, as part of efforts towards the elimination of the waterborne disease in the country. The campaign launched targets to vaccinate 1,038,000 eligible people from one year and above in the Zambian capital and follows vaccination campaigns conducted in seven of the 11 cholera-prone districts in the country.
- Expanding immunization programs: Expanding immunization programs could provide a great opportunity for growth in the Zambia cholera vaccines market. Cholera remains a major public health problem in Zambia, where outbreaks are still common especially during the rainy season. According to the World Health Organization (WHO), Zambia reported over 6,700 cholera cases and 118 deaths from January to October 2020 alone. With such a high disease burden, scaling up vaccination programs could help contain the spread of the disease. Vaccination programs in Zambia are limited in scale and coverage. They primarily focus on reactive vaccination during outbreaks rather than establishing sustained immunization infrastructure. This temporary, outbreak-based approach is unable to achieve long-term protection or herd immunity in communities at risk. A few oral cholera vaccination campaigns have been conducted with support from international organizations like the WHO, but vaccination levels remain low across the country. Expanding these preliminary immunization efforts into a standardized, multi-year routine cholera vaccination strategy could drive significant and sustained demand for cholera vaccines.
Zambia Cholera Vaccines Market - Restraints
- High cost for drug development: High cost of drug development is one of the major restraints impacting the growth of Zambia cholera vaccines market. Developing an effective vaccine involves extensive research and clinical trials which requires huge investments. Antibiotics are the only available treatment options for cholera vaccines, and many pharmaceutical companies are working on developing non-antibiotic alternatives. For important market players, creating a new class of medications will present numerous growth prospects, and will also necessitate significant financial outlays for the research and development (R&D) of innovative treatments. The comparatively large investment needs could impede market expansion.
- Longer time required for production of vaccine: The length of time needed to produce a batch of vaccines can serve as a market restriction. The duration varies significantly depending on the manufacturing size, ranging from 41.2 hours for a 1 L process to 48.2 hours for a 30 L process. As a result, it limits the market
- Counterbalance: The key market players should focus on developing technologies which will reduce time and cost for production of vaccines.
U.S.: 
U.K. : 
India : 
